Chemistry:Azemiglitazone
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | Azemiglitazone potassium; MSDC-0602; MSDC-0602K |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H17NO5S |
| Molar mass | 371.41 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Azemiglitazone (MSDC-0602) is a novel insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius Therapeutics for type 2 diabetes and non-alcoholic fatty liver disease.[1][2][3] It is formulated as its potassium salt, azemiglitazone potassium (MSDC-0602K).
References
- ↑ Colca, Jerry R.; Lee, Bo Hyun; Iwashita, Julie S.; Dittrich, Howard C.; Harrison, Stephen A. (1 June 2020). "1090-P: MSDC-0602k, a New Oral Insulin Sensitizer in Insulin Resistant NASH Patients with and without Type 2 Diabetes (T2D)". Diabetes 69 (Supplement_1). doi:10.2337/db20-1090-P.
- ↑ Harrison, Stephen A.; Alkhouri, Naim; Davison, Beth A.; Sanyal, Arun; Edwards, Christopher; Colca, Jerry R.; Lee, Bo Hyun; Loomba, Rohit et al. (April 2020). "Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase IIb study". Journal of Hepatology 72 (4): 613–626. doi:10.1016/j.jhep.2019.10.023.
- ↑ Kamm, Dakota R.; Pyles, Kelly D.; Sharpe, Martin C.; Healy, Laura N.; Colca, Jerry R.; McCommis, Kyle S. (January 2021). "Novel insulin sensitizer MSDC-0602K improves insulinemia and fatty liver disease in mice, alone and in combination with liraglutide". Journal of Biological Chemistry 296: 100807. doi:10.1016/j.jbc.2021.100807. PMID 34022222.
 |  |
